ПIДВИЩЕНI ЦИРКУЛЯТОРНI РIВНI ОСТЕОПРОТЕГЕРИНУ У ХВОРИХ НА ЦУКРОВИЙ ДIАБЕТ 2 ТИПУ: АСОЦIАЦIЯ З ПАРАМЕТРАМИ МЕТАБОЛIЧНОГО ТА ГОРМОНАЛЬНОГО ДИСБАЛАНСУ, ПРОЯВАМИ СУДИННИХ УСКЛАДНЕНЬ

Автор(и)

DOI:

https://doi.org/10.21856/j-PEP.2012.1.01

Ключові слова:

остеопротегерин, цукровий дiабет 2 типу, iнсулiнорезистентнiсть, маркери атерогенезу

Анотація

Дослiджено 61 хворого на цукровий дiабет 2 типу з надлишковою масою тiла або ожирiнням, середнього вiку, гормональними та метаболiчними проявами iнсулiнорезистентностi (гiперiнсулiнемiя натще, пiдвищенi iндекси HOMA-IR та рiвнi вiльних жирних кислот, гiпоадипонектинемiя, гiпертриглiцеридемiя). Верифiковано значуще пiдвищення рiвнiв остеопротегерину в циркуляцiї, асоцiйоване з наявнiстю макросудинних ускладнень (iшемiчна хвороба серця, гiпертонiчна хвороба). Визначена пряма кореляцiя остеопротегерину iз ретинол-зв’язуючим протеiном 4, фетуiном-А та програнулiном. Обґрунтована доцiльнiсть залучення циркуляторних рiвнiв остеопротегерину до кластеру бiомаркерiв кардiоваскулярного ризику.

Посилання

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density [Text] / W. S. Simonet, D. L. Lacey, C. R. Dunstan [et al.] // Cell. —1997. — Vol. 89. — P. 309–319.

Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis [Text] / E. Tsuda, M. Goto, S. Mochizuki [et al.] // Biochem. Bioph. Res. Comm. — 1997. — Vol. 234. — P. 137–142.

TR1, a new member of the tumor necrosis factor receptor superfamily, induces fibroblast proliferation and inhibits osteoclastogenesis and bone resorption [Text] / B. S. Kwon, S. Wang, N. Udagawa [et al.] // FASEB J. — 1998. — Vol. 12. — P. 845–854.

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation [Text] / D. L. Lacey, E. Timms, H. L. Tan [et al.] // Cell. —1998. — Vol. 93. — P. 165–176.

Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand [Text] / H. Hsu, D. L. Lacey, C. R. Dunstan [et al.] // Proc. Natl. Acad. Sci. — 1999. — Vol. 96. — P. 3540–3545.

Hofbauer, L. C. The role of receptor activator of nuclear factor-κB ligand and osteoprogerin in pathogenesis and treatment of metabolic bone disease [Text] / L. C. Hofbauer, A. E. Heufelder // J. Clin. Endocrinol. Metabol. — 2000. — Vol. 85. — P. 2355–2363.

RANKL-RANK signaling in osteoclastogenesis and bone disease [Text] / T. Wada, T. Nakashima, N. Hiroshi [et al.] // Trends. Mol. Med. — 2006. — Vol. 12. — P. 17–25.

A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function [Text] / D. M. Anderson, E. Marakovsky, W. L. Billingsley [et al.] // Nature. — 1997. — Vol. 390. — P. 175–179.

OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis [Text] / Y. Y. Kong, H. Yoshida, I. Sarosi [et al.] // Nature. — 1999. — Vol. 397. — P. 315–323.

Kong, Y. Y. Osteoprotegerin ligand: a regulator of immune responses and bone physiology [Text] / Y. Y. Kong, W. J. Boyle, J. M. Penninger // Immunol. Today. — 2000. — Vol. 21. — P. 495–502.

Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL [Text] / J. G. Emery, P. McDonnell, M. B. Burke [et al.] // J. Biol. Chem. — 1998. — Vol. 273. — P. 14363–14367.

Osteoprotegerin is an αvβ3-induced NF-κB-dependent survival factor for endothelial cells [Text] / U. M. Malyankar, M. Scatena, K. L. Suchland [et al.] // J. Biol. Chem. — 2000. — Vol. 275. — P. 20959–20962.

Receptor activator of NF-κB and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis [Text] / P. Collin-Osdoby, L. Rothe, F. Anderson [et al.] // J. Biol. Chem. — 2001. — Vol. 276. — P. 20659–20672.

Effects of immunosuppressants on receptor activator of NF-κB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells [Text] / L. C. Hofbauer, C. Shui, B. L. Riggs [et al.] // Biochem. Biophys. Res. Commun. — 2001. — Vol. 280. — P. 334–339.

Olesen, P. Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNFalpha [Text] / P. Olesen, T. Ledet, L. M. Rasmussen // Diabetologia. — 2005. — Vol. 48. — P. 561–568.

Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification [Text] / N. Bucay, I. Sarosi, C. R. Dunstan [et al.] // Genes Dev. — 1998. — Vol. 12. — P. 1260–1268.

Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease [Text] / S. Jono, Y. Ikari, A. Shioi [et al.] // Circulation. — 2002. — Vol. 106. — P. 1192–1194.

Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications (Erratum) [Text] / S. T. Knudsen, C. H. Foss, P. L. Poulsen [et al.] // Europ. J. Endocrinol. — 2003. — Vol. 149. — P. 161.

Increased osteoprotegerin serum levels in men with coronary artery disease [Text] / M. Schoppet, A. M. Sattler, J. R. Schaefer [et al.] // J. Clin. Endocrinol. Metabol. — 2003. — Vol. 88. — P. 1024–1028.

Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease [Text] / S. Kiechi, G. Schett, G. Wenning [et al.] // Circulation. — 2004. — Vol. 109. — P. 2175–2180.

Browner, W. S. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women [Text] / W. S. Browner, L. Y. Lui, S. R. Cummings // J. Clin. Endocrinol. Metabol. — 2001. —Vol. 86. — P. 631–637.

Collin-Osdoby, P. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin [Text] / P. Collin-Osdoby // Circ. Res. — 2004. — Vol. 95. — P. 1046–1057.

Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients [Text] / A. Avignon, A. Sultan, C. Piot [et al.] // Diabetes Care. — 2005. —Vol. 28. — № 9. — P. 2176–2180.

Osteoprotegerin: a novel independent marker for silent myocardial ischemia in asymptomatic diabetic patients [Text] / A. Avignon, A. Sultan, C. Piot [et al.] // Diabetes Care. — 2007. — Vol. 30. —P. 3934–3939.

Osteoprotegerin, thiazolidinediones treatment, and silent myocardial ischemia in type 2 diabetic patients [Text] / A. Sultan, A. Avignon, F. Galtier [et al.] // Diabetes Care. — 2008. — Vol. 31. — P. 593–595.

Atherosclerosis: basic mechanisms. Oxidation, in-flammation, and genetics [Text] / J. A. Berliner, M. Navab, A. M. Fogelman [et al.] // Circulation. —1995. — Vol. 91. — P. 2488–2496.

Medial artery calcification. A neglected harbinger of cardiovascular complications in non-insulin-dependent diabetes mellitus [Text] / S. Lehto, L. Niskanen, M. Suhonen [et al.] // Arterioscler. Thromb. Vasc. Biol. — 1996. — Vol. 16. — P. 978–983.

Hofbauer, L. C. Osteoprotegerin: a link between osteoporosis and arterial calcification? [Text] / L. C. Hofbauer, M. Schoppet // Lancet. — 2001. — Vol. 358. — P. 257–259.

Nybo, M. Osteoprotegerin released from the vascular wall from vascular smooth muscle cells [Text] / M. Nybo, L. M. Rasmussen // Atherosclerosis. — 2008. — Vol. 201. — P. 33–35.

Low blood osteoprotegerin levels are a predictor to poor prognosis in Japanese patients on hemodialysis due to diabetic nephropathy [Text] / K. Yokoyama, T. Shigematsu, K. Miyaki [et al.] // Therapeutic Apheresis and Dialysis. — 2008. — Vol. 12. —P. 259–260.

Jorgensen, G. M. Acute hyperinsulinemia decreases plasma osteoprotegerin with diminished effect in type 2 diabetes and obesity [Text] / G. M. Jorgensen, B. Vind, M. Nybo // Europ. J. Endocrinol. —2009. — Vol. 161. — P. 95–101.

Kannel, W. B. Diabetes and cardiovascular disease; the Framingham study [Text] / W. B. Kannel, D. L. McGee // J. Am. Med. Ass. — 1979. —Vol. 241. — P. 2035–2038.

Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes [Text] / F. B. Hu, M. J. Stampfer, S. M. Haffner // Diabetes Care. —2002. — Vol. 25. — № 7. — P. 1129–1134.

Increased circulating levels of osteoclastogenesis-inhibitory factor (osteoprotegerin) in patients with chronic renal failure [Text] / J. J. Kazama, T. Shigematsu, K. Yano [et al.] // Am. J. Kidney. Dis. —2002. — Vol. 39. — P. 525–532.

Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status [Text] / P. Szulc, L. C. Hofbauer, A. E. Heufelder [et al.] // J. Clin. Endocrinol. Metabol. — 2001. —Vol. 86. — P. 3162–3165.

Costantini, D. On the measurement of circulating antioxidant capacity and the nightmare of uric acid [Text] / D. Costantini // Meth. Ecol. Evol. —2011. — Vol. 2. — P. 321–325.

Schell, Th. Oxidative stress, implications in equine orthopedic disease, insulin resistance and a potential target for therapy [Text] / Th. Schell, C. Neatu // JAHYMA. — 2010. — Vol. 29. — № 1. — P. 11–15.

Richter, R. Determination of paraoxonase (pon 1) status requires more than genotyping [Text] / R. Richter, C. E. Furlong // Pharmacogenetics. —1999. — Vol. 9. — P. 745–753.

Matthews, D. R. Homeostasis model assessement: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man [Text] / D. R. Matthews, J. P. Hosker, A. S. Rudenski // Diabetologia. — 1985. — Vol. 28. — P. 412–419.

Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans [Text] / A. Katz, S. S. Nambi, K. Mather [et al.] // J. Clin. Endocrinol. Metabol. — 2000. —Vol. 85. — P. 2402–2410.

Osteoprotegerin in relation to body weight, lipid parameters insulin sensitivity, adipocytokines, and C-reactive protein in obese and non-obese young individuals: results from both cross-sectional and interventional study [Text] / M. H. Gannage-Yared, C. Yaghi, B. Habre [et al.] // Europ. J. Endocrinol. — 2008. — Vol. 158. — P. 353–359.

Circulating osteoprotegerin is correlated with lipid profile, insulin sensitivity, adiponectin and sex steroids in an ageing male population [Text] / M. H. Gannage-Yared, F. Fares, M. Semaan [et al.] // Clin. Endocrinol. — 2006. — Vol. 64. — P. 652–658.

Inflammatory mediators in morbidly obese subjects: associations with glucose abnormalities and changes after oral glucose [Text] / D. Hofso, T. Ueland, H. Hager [et al.] // Europ. J. Endocrinol. — 2009. —Vol. 161. — P. 451–458.

Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus [Text] / J. S. Park, M. H. Cho, J. S. Nam [et al.] // Europ. J. Endocrinol. — 2011. — Vol. 164. —№ 1. — P. 69–74.

Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signalling pathway [Text] / X. H. Luo, L. J. Guo, H. Xie [et al.] // J. Bon. Min. Res. — 2006. –Vol. 21. — P. 1648–1658.

Serum osteoprotegerin levels are associated with inflammation and pulse wave velocity [Text] / S. M. Kim, J. Lee, O. H. Ryu [et al.] // Clin. Endocrinol. — 2005. — Vol. 63. — P. 594–598.

The relationship between plasma osteoprotegerin and endothelium dependent arterial dilatation in type 2 diabetes [Text] / G. D. Xiang, L. Xu, L. S. Zhao [et al.] // Diabetes. — 2006. — Vol. 55. —P. 2126–2131.

Boneti, P. O. Endothelial dysfunction, a marker of atherosclerotic risk [Text] / P. O. Boneti, L. O. Lerman, A. Lerman // Arterioscl. Thromb. Vascul. Biol. — 2003. — Vol. 23. — P. 168–175.

##submission.downloads##

Опубліковано

2012-03-15

Як цитувати

Горшунська, М. (2012). ПIДВИЩЕНI ЦИРКУЛЯТОРНI РIВНI ОСТЕОПРОТЕГЕРИНУ У ХВОРИХ НА ЦУКРОВИЙ ДIАБЕТ 2 ТИПУ: АСОЦIАЦIЯ З ПАРАМЕТРАМИ МЕТАБОЛIЧНОГО ТА ГОРМОНАЛЬНОГО ДИСБАЛАНСУ, ПРОЯВАМИ СУДИННИХ УСКЛАДНЕНЬ. Проблеми ендокринної патології, 39(1), 5–15. https://doi.org/10.21856/j-PEP.2012.1.01

Номер

Розділ

КЛІНІЧНА ЕНДОКРИНОЛОГІЯ

Статті цього автора (авторів), які найбільше читають

1 2 > >> 

Схожі статті

1 2 3 4 5 6 7 8 9 10 > >> 

Ви також можете розпочати розширений пошук схожих статей для цієї статті.